Abstract: We screen the Hong Kong-listed mainland stocks ahead of the HSCEI August 2026 review. The screen produces one ADD and one DELETE, and the DELETE fires only if the ADD lands. We note that the committee skipped the same ADD candidate last review but re-iterate our call.
CHINA SHENHUA, CSPC Pharma, CHINA RESOURCES LAND, SINO BIOPHARMACEUTICAL, HUA HONG SEMI, J&T EXPRESS, PSBC, SENSETIME, LI AUTO, ZTO EXPRESS, WUXI BIOLOGICS, SHENZHOU INTERNATIONAL, PICC P&C, Sunny Optical, KE, CPIC, CITIC, ENN ENERGY, BANKCOMM, HANSOH PHARMACEUTICAL, CATL, SINOPEC, CMOC, BEONE MEDICINES LTD-H, LAOPU GOLD, JD Health, HAIER SMARTHOME, COLI, CHINA TELECOM, China Unicom, SINO LAND, CHINA RESOURCES POWER, HORIZONROBOT, XPENG, LENOVO, AKESO, CITIC BANK, YUM CHINA
Research on index reviews and inclusion events across Asia Pacific, including MSCI, Hang Seng (HSI, HSCEI, HSCI), HS TECH, CSI 300, STAR50, NIFTY and Stock Connect changes. Coverage runs from rebalance forecasts through post-announcement positioning, pre-implementation updates and post-implementation reviews, using the price patterns of past events.
Interested in the full report? Get in touch with our team.
We will review your request. Once approved, the report will be sent to your company email.
Thank you! We will review your request and email the report to you, usually within 1 business day.